Neuroblastoma screening in the United States: Results of the Texas outreach program for neuroblastoma screening

Cancer

Volumn 82, Issue 8, 1998, Pages 1593-1602

  Ater, Joann L ^a,c   Gardner, Kristina L ^a   Foxhall, Lewis E ^a   Therrell Jr , Brad L ^b   Archie Bleyer, W ^a  

^a UNIVERSITY OF TEXAS   (United States)

^b TEXAS DEPARTMENT OF STATE HEALTH SERVICES   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Cancer; Child; Early detection; Enzyme linked immunoadsorbent assay; Homovanillic acid; Infant; Neuroblastoma; Public health; Screening; Vanillylmandelic acid

Indexed keywords

HOMOVANILLIC ACID; VANILMANDELIC ACID;

ARTICLE; CANCER INCIDENCE; CANCER SCREENING; EARLY DIAGNOSIS; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; INFANT; MAJOR CLINICAL STUDY; NEUROBLASTOMA; PATIENT COMPLIANCE; PRIORITY JOURNAL; UNITED STATES; URINE LEVEL;

ENZYME-LINKED IMMUNOSORBENT ASSAY; FEASIBILITY STUDIES; FEMALE; HOMOVANILLIC ACID; HUMANS; INFANT; MALE; MASS SCREENING; NEUROBLASTOMA; SENSITIVITY AND SPECIFICITY; TEXAS; VANILMANDELIC ACID;

EID: 0032522954     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(19980415)82:8<1593::AID-CNCR23>3.0.CO;2-Z     Document Type: Article

References (26)

1. Young JL, Miller RW. Incidence of malignant tumors in U.S. children. J Pediatr 1975;86:254-8.
2. Levy HL, Karolkewicz V, Houghten SA, MacCready RA. Screening the normal population in Massachusetts for phenylketonuria. N Engl J Med 1970;282:1455-8.
3. Levy HL. Screening in galactosemia. In: Burman D, Holton JB, Pennock CA, editors. Inherited disorders of carbohydrate metabolism. Lancaster, England: MTP Press, Falcon House, 1980:133.
4. Tuchman M, Ramnaraine MLR, Woods WG, Krivit W. Three years of experience with random urinary homovanillic and vanillylmandelic acid levels in the diagnosis of neuroblastoma. Pediatrics 1987;79:203-5.
5. Kinoshita Y, Yamada S, Haraguchi K, Takayanagi T, Mori Y, Takahashi T, et al. Determination of vanillylmandelic acid, vanillactic acid and homovanillic acid in dried urine on filter paper discs by high performance liquid chromatography with coulometric electrochemical detection for neuroblastoma screening. Clin Chem 1988;34:2228-30.
6. Kuroda M, Sugi M, Ikeda T, Fujimoto M, Yokomori K, Amano J, et al. Enzyme immunoassay of vanillylmandelic acid (VMA) in urine. Biogenic Amines 1990;7:257-63.
7. Takeda T. History and current status of neuroblastoma screening in Japan. Med Pediatr Oncol 1989;17:361-3.
8. Sawada T, Sugimoto T, Kawakatsu H, Matsumura T, Matsuda Y. Mass screening for neuroblastoma in Japan. Pediatr Hematol Oncol 1991;8:93-109.
9. Hanawa Y, Sawada T, Tsunoda A. Decrease in childhood neuroblastoma death in Japan. Med Pediatr Oncol 1990; 18:472-5.
10. Nishi M, Miyake H, Takeda T, Shimada M, Takasugi N, Sato Y, et al. Effects of mass screening of neuroblastoma in Sapporo City. Cancer 1987;60:433-6.
11. Sawada T. Past and future of neuroblastoma screening in Japan. Am J Pediatr Hematol Oncol 1992;14:320-6.
12. Hayashi Y, Ohi R, Yaoita S. Problems of neuroblastoma screening for 6 month olds and results of second screening for 18 month olds. J Pediatr Surg 1995;30:467-70.
13. Seviour JA, McGill AC, Craft AW, Parker L. Screening for neuroblastoma in the northern region of England. Laboratory aspects. Am J Pediatr Hematol Oncol 1992;14:332-6.
14. Treuner J, Shilling FH. Neuroblastoma mass screening, the arguments for and against. Eur J Cancer 1995;31A:565-8.
15. Takeuchi LA, Hachitanda Y, Woods WG, Tuchman M, Lemieux B, Brisson L, et al. Screening for neuroblastoma in North America. Preliminary results of a pathology review from the Quebec Project. Cancer 1995;76:2363-71.
16. Woods WG, Tuchman M, Bernstein ML, Leclerc JM, Brisson L, Look T, et al. Screening for neuroblastoma in North America, 2-year results from the Quebec Project. Am J Pediatr Hematol Oncol 1992;14:312-9.
17. Woods WG, Tuchman M, Robison LL, Bernstein M, Leclerc J-M, Brisson LC, et al. A population-based study of the usefulness of screening for neuroblastoma. Lancet 1996; 348:1682-7.
18. Yokomori K, Hori T, Tsuchida Y, Kuroda M, Yoshioka M. A new urinary mass screening system for neuroblastoma in infancy by use of monoclonal antibodies against VMA and HVA. J Pediatr Surg 1989;24:391-4.
19. Tuchman M, Fisher EJ, Heisel MA, Woods WG. Feasibility study for neonatal neuroblastoma screening in the United States. Med Pediatr Oncol 1989;17:258-64.
20. Watanabe N, Naruse H, Umehashi T, Tazaki R, Hanai J, Fukushi M, et al. Comparison of HPLC and ELISA methods in neuroblastoma screening. Screening 1993;2:33-42.
21. Magnotti RA, Stephens GW, Rogers RK, Pesce AJ. Microplate measurement of urinary albumin and creatinine. Clin Chem 1989;35:1371-5.
22. Ater JL, Gardner KL, Altmiller D, Ali-Osman F. Preliminary evaluation of an enzyme immunoassay for vanillylmandelic acid (VMA) and homovanillic acid (HVA) for utilization in the Houston neuroblastoma screening program. Presented at the Second International Symposium on Neuroblastoma Screening, Minneapolis, Minnesota, May 22-24, 1991.
23. Mizuta M, Unisa H. Utilization of wet paper urine specimens in mass screening for neuroblastoma: the problem of bacterial contamination. Nippon Koshu Eisei Zasshi 1988;35:79-83.
24. Craft AW, Parker L, Dale G, McGill AC, Seviour JA, Bell S, et al. A pilot study of screening for neuroblastoma in the north of England. Am J Pediatr Hematol Oncol 1992;14:337-41.
25. Bostick RM, Sprafka JM, Virnig BA, Potter JD. Predictors of cancer prevention attitudes and participation in cancer screening examinations. Prev Med 1994;23:816-26.
26. Reed CA, Selleck CS. The role of midlevel providers in cancer screening. Med Clin North Am 1996;80:135-44.